(NASDAQ: ATYR) Atyr Pharma's forecast annual revenue growth rate of 628.37% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Atyr Pharma's revenue in 2025 is $235,000.On average, 1 Wall Street analysts forecast ATYR's revenue for 2025 to be $1,066,303,344, with the lowest ATYR revenue forecast at $1,066,303,344, and the highest ATYR revenue forecast at $1,066,303,344. On average, 3 Wall Street analysts forecast ATYR's revenue for 2026 to be $2,176,680,560, with the lowest ATYR revenue forecast at $1,119,618,511, and the highest ATYR revenue forecast at $3,012,306,947.
In 2027, ATYR is forecast to generate $8,581,520,454 in revenue, with the lowest revenue forecast at $1,777,172,240 and the highest revenue forecast at $14,546,154,784.